Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE reduced-intensity immunotherapy trial across renal cancer and melanoma
ISRCTN79455488Phase 2Completed
- Sponsor
- University College London
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab and pembrolizumab in renal cell carcinoma (RCC) and melanoma (2 arms), sponsored by University College London. Primary endpoint: Progression-free survival. Started May 2022; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on ISRCTN79455488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79455488.